Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GNRHR | P30968 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285249 | 0.89 | CYP3A4 (0.75) | CYP3A4L3MBTL1LMNAGNRHRALDH1A1 | |
| SCHEMBL12515758 | 0.88 | CYP3A4 (0.65) | CYP3A4L3MBTL1MAPTLMNASMN1; SMN2 | |
| SCHEMBL12515776 | 0.88 | CYP3A4 (0.60) | CYP3A4LMNASMN1; SMN2GNRHRALDH1A1 | |
| SCHEMBL349965 | 0.86 | CYP3A4 (0.80) | CYP3A4L3MBTL1MAPTLMNASMN1; SMN2 | |
| SCHEMBL12515775 | 0.85 | CYP3A4 (0.59) | CYP3A4LMNASMN1; SMN2GNRHRALDH1A1 | |
| SCHEMBL2280514 | 0.84 | TLR7 (0.41) | CYP3A4MAPTTLR7DRD2GAA | |
| SCHEMBL2277912 | 0.82 | ALDH1A1 (0.43) | MAPTLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL349715 | 0.80 | CYP3A4 (0.65) | CYP3A4L3MBTL1MAPTLMNASMN1; SMN2 | |
| SCHEMBL14733237 | 0.80 | CYP3A4 (0.77) | CYP3A4L3MBTL1LMNASMN1; SMN2GNRHR | |
| SCHEMBL2361747 | 0.79 | CYP3A4 (0.85) | CYP3A4L3MBTL1LMNASMN1; SMN2GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | CYP3A4 1367/4885L3MBTL1 4395/4885MAPT 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.